NO20082075L - Anti-hyperkolesterolemiske forbindelser - Google Patents

Anti-hyperkolesterolemiske forbindelser

Info

Publication number
NO20082075L
NO20082075L NO20082075A NO20082075A NO20082075L NO 20082075 L NO20082075 L NO 20082075L NO 20082075 A NO20082075 A NO 20082075A NO 20082075 A NO20082075 A NO 20082075A NO 20082075 L NO20082075 L NO 20082075L
Authority
NO
Norway
Prior art keywords
compounds
cholesterol
hypercholesterolemic compounds
hypercholesterolemic
esters
Prior art date
Application number
NO20082075A
Other languages
English (en)
Inventor
Robert J Devita
Gregori J Moriello
Peter Lin
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20082075L publication Critical patent/NO20082075L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Denne oppfinnelsen tilveiebringer kolesterol-absorpsjonsinhibitorer med formel I og de farmasøytisk akseptable saltene og esterne derav. Forbindelsene er anvendbare til senking av plasmakolesterolnivåer, særlig LDL-kolesterol, og til behandling og forebyggelse av aterosklerose og aterosklerotiske sykdomstilfeller.
NO20082075A 2005-10-05 2008-05-02 Anti-hyperkolesterolemiske forbindelser NO20082075L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72378105P 2005-10-05 2005-10-05
PCT/US2006/038551 WO2007044318A2 (en) 2005-10-05 2006-09-29 Anti-hypercholesterolemic compounds

Publications (1)

Publication Number Publication Date
NO20082075L true NO20082075L (no) 2008-07-04

Family

ID=37845278

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082075A NO20082075L (no) 2005-10-05 2008-05-02 Anti-hyperkolesterolemiske forbindelser

Country Status (25)

Country Link
US (2) US20090137546A1 (no)
EP (1) EP1934175B1 (no)
JP (1) JP4879991B2 (no)
KR (1) KR20080050610A (no)
CN (1) CN101277930A (no)
AR (1) AR058068A1 (no)
AT (1) ATE488495T1 (no)
AU (1) AU2006302584B2 (no)
BR (1) BRPI0616834A2 (no)
CA (1) CA2624481C (no)
CR (1) CR9903A (no)
DE (1) DE602006018341D1 (no)
DO (1) DOP2006000211A (no)
EA (1) EA200801008A1 (no)
ES (1) ES2354460T3 (no)
GT (1) GT200600444A (no)
IL (1) IL190434A0 (no)
MA (1) MA30006B1 (no)
NO (1) NO20082075L (no)
PE (1) PE20070493A1 (no)
SV (1) SV2009002863A (no)
TN (1) TNSN08153A1 (no)
TW (1) TW200806623A (no)
WO (1) WO2007044318A2 (no)
ZA (1) ZA200802587B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176193B2 (en) * 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
EP1699759B1 (en) * 2003-12-23 2010-10-20 AstraZeneca AB Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
GB0329778D0 (en) * 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
AU2004308332B2 (en) * 2003-12-23 2008-04-10 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds
UY29607A1 (es) * 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
SA06270191B1 (ar) * 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AR057383A1 (es) * 2005-06-22 2007-12-05 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
AR054482A1 (es) * 2005-06-22 2007-06-27 Astrazeneca Ab Derivados de azetidinona para el tratamiento de hiperlipidemias
AR057072A1 (es) * 2005-06-22 2007-11-14 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
AR057380A1 (es) * 2005-06-22 2007-11-28 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
TW200806623A (en) * 2005-10-05 2008-02-01 Merck & Co Inc Anti-hypercholesterolemic compounds
DE102005055726A1 (de) * 2005-11-23 2007-08-30 Sanofi-Aventis Deutschland Gmbh Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
AR060623A1 (es) * 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
EP2124549A4 (en) * 2006-12-20 2010-01-20 Merck & Co Inc ANTIHYPERCHOLESTERINAMIC COMPOUNDS
DE102009023046B4 (de) 2008-05-30 2016-10-13 Hyundai Motor Company Automatisch schaltbares Getriebe eines Kraftfahrzeuges
WO2010056788A1 (en) * 2008-11-17 2010-05-20 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT67341A (en) * 1991-07-23 1995-03-28 Schering Corp Substituted beta-lactam compounds useful as hypocholesterolemic agents, pharmaceutical compositions containing the same and process for the production thereof
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
JPH10501811A (ja) * 1994-06-20 1998-02-17 シェーリング コーポレイション 低コレステロール化剤として有用な置換アゼチジノン化合物
US5624920A (en) * 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
DE50111751D1 (de) * 2000-12-21 2007-02-08 Sanofi Aventis Deutschland Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
TWI291957B (en) * 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
US7176194B2 (en) * 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7176193B2 (en) * 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
ATE406364T1 (de) * 2003-03-07 2008-09-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
JP2005015434A (ja) * 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
AU2004308332B2 (en) * 2003-12-23 2008-04-10 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds
WO2006086562A2 (en) * 2005-02-09 2006-08-17 Microbia, Inc. Phenylazetidinone derivatives
CN101198338A (zh) * 2005-06-15 2008-06-11 默克公司 抗高胆固醇血化合物
TW200806623A (en) * 2005-10-05 2008-02-01 Merck & Co Inc Anti-hypercholesterolemic compounds
DE102005055726A1 (de) * 2005-11-23 2007-08-30 Sanofi-Aventis Deutschland Gmbh Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
CN101535249A (zh) * 2006-11-02 2009-09-16 塞诺菲-安万特德国有限公司 具有改善的药理性质的新的哌嗪-1-磺酸取代的二苯基氮杂环丁酮

Also Published As

Publication number Publication date
CR9903A (es) 2008-07-29
DE602006018341D1 (de) 2010-12-30
EP1934175A2 (en) 2008-06-25
ZA200802587B (en) 2009-06-24
TNSN08153A1 (en) 2009-10-30
KR20080050610A (ko) 2008-06-09
AU2006302584B2 (en) 2011-10-13
BRPI0616834A2 (pt) 2016-08-23
SV2009002863A (es) 2009-02-19
WO2007044318A2 (en) 2007-04-19
GT200600444A (es) 2007-05-04
EA200801008A1 (ru) 2009-02-27
US20090137546A1 (en) 2009-05-28
WO2007044318A3 (en) 2007-07-12
AU2006302584A1 (en) 2007-04-19
AR058068A1 (es) 2008-01-23
PE20070493A1 (es) 2007-06-13
ES2354460T3 (es) 2011-03-15
JP4879991B2 (ja) 2012-02-22
US7704988B2 (en) 2010-04-27
TW200806623A (en) 2008-02-01
IL190434A0 (en) 2008-11-03
JP2009511475A (ja) 2009-03-19
CA2624481C (en) 2012-04-03
MA30006B1 (fr) 2008-12-01
EP1934175B1 (en) 2010-11-17
ATE488495T1 (de) 2010-12-15
US20070078098A1 (en) 2007-04-05
CN101277930A (zh) 2008-10-01
CA2624481A1 (en) 2007-04-19
DOP2006000211A (es) 2007-05-31

Similar Documents

Publication Publication Date Title
NO20082075L (no) Anti-hyperkolesterolemiske forbindelser
WO2006138163A3 (en) Anti-hypercholesterolemic compounds
WO2005062824A3 (en) Anti-hypercholesterolemic compounds
WO2007008529A3 (en) Celullar cholesterol absorption modifiers
WO2006110816A3 (en) 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
WO2007059230A3 (en) Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
WO2006121861A3 (en) Biphenylazetidinone cholesterol absorption inhibitors
WO2007008541A3 (en) Cellular cholesterol absorption modifiers
ZA200710609B (en) Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
NO20062561L (no) Kinoliner nyttige for behandling av kardiovaskulaere sykdommer
NO20092711L (no) Metoder for anvendelse av cyclopaminanaloger
IL187738A0 (en) New 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
NO20082088L (no) Azetidiner som MEK-inhibitorer for behandling av proliferative sykdommer
NO20090202L (no) Prolylhydroksylaseinhibitorer
ZA200710604B (en) Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
UA96126C2 (ru) Соединение для ингибирования активности rho киназы, фармацевтическая композиция, которая содержит такое соединение, и способ ингибирования активности rho киназы
DE602006010243D1 (de) 4-(Phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamid Derivate als MEK Inhibitoren zur Behandlung von hyperproliferativen Erkrankungen
NO20083923L (no) Pyrazolkinoloner er potente parp-inhibitorer
WO2009073497A3 (en) Prolyl hydroxylase inhibitors
NO20060632L (no) Nye forbindelser og sammensettinger som omfatter steroler og/eller stanoler og kolesterolbiosynteseinhibitorer og anvendelse av disse i behandling eller forebygging av en rekke sykdommer og tilstander
WO2008073452A8 (en) Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors
WO2008130600A3 (en) Quinolones and azaquinolones that inhibit prolyl hydroxylase
NO20064344L (no) Caspaseinhibitorer og anvendelser derav
NO20056218L (no) Substituerte pyrrolderivater og anvendelse derav som HMF-CoA reduktase-inhibitorer
WO2008057336A3 (en) Heterocyclyl-substituted anti-hypercholesterolemic compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application